Cover Image
close this bookUNAIDS-Sponsored Regional Workshops to Discuss Ethical Issues in Preventive HIV Vaccine Trials (UNAIDS, 2000, 52 p.)
close this folderWORKSHOP REPORTS
close this folderOURO PRETO, BRAZIL, 1-3 APRIL, 1998
View the document1. Vulnerability to Harm or Exploitation
View the document2. Collaboration in Phase I/II (Safety and Immunogenicity) Trials
View the document3. Phase III (efficacy) Trials
View the document4. Review of Vaccine Trials
View the document5. Candidate Vaccine Choice
View the document6. Community
View the document7. Intellectual Property
View the document8. Control Arm in Trials
View the document9. Informed Consent
View the document10. Gender, Pregnancy and Breast-Feeding
View the document11. Counselling, Treatment and Care
View the document12. Access and Availability of Vaccine
View the document13. Items Not Discussed

7. Intellectual Property


A discussion about intellectual property needs to take place early in the process of proposal development. It may be reasonable for the host country to claim a right to intellectual property if its participation in the trial is deemed essential for the development of the particular candidate vaccine.


Intellectual property may become an important commodity in the negotiation of vaccine availability to the host country following the trial. However, access to a successful vaccine following the trial should be dealt with separately from the question of who has the right to intellectual property.


It is not clear who in the host country (investigators, government, and population) should have a claim to the intellectual property rights, though a majority was of the opinion that this should not be the exclusive property of the investigators.